Spark Therapeutics Inc. (ONCE)

104.11
NASDAQ : Health Technology
Prev Close 104.40
Day Low/High 102.96 / 104.82
52 Wk Low/High 34.53 / 114.20
Avg Volume 422.40K
Exchange NASDAQ
Shares Outstanding 37.75M
Market Cap 3.94B
EPS -2.10
P/E Ratio 55.83
Div & Yield N.A. (N.A)
Illumina Shares Spike on Strong Earnings, Upside Still Remains: Biotech Movers

Illumina Shares Spike on Strong Earnings, Upside Still Remains: Biotech Movers

Illumina, Spark Therapeutics and Endo International were among the biotech stock movers in premarket trading on Aug. 2.

Spark Therapeutics Submits Marketing Authorization Application To European Medicines Agency For Investigational LUXTURNA™ (voretigene Neparvovec)

Spark Therapeutics Submits Marketing Authorization Application To European Medicines Agency For Investigational LUXTURNA™ (voretigene Neparvovec)

Potential for first gene therapy for a genetic disease to be approved in both the U.S. and EU

These Are the Best Growth Stocks Right Now in Biotech

These Are the Best Growth Stocks Right Now in Biotech

Top names.

Spark Therapeutics Announces Publication In The Lancet Of Pivotal Phase 3 Clinical Trial Data For Investigational Voretigene Neparvovec

Spark Therapeutics Announces Publication In The Lancet Of Pivotal Phase 3 Clinical Trial Data For Investigational Voretigene Neparvovec

Data show that 65 percent of participants demonstrated the maximal improvement in the clinical trial's primary endpoint, bilateral multi-luminance mobility testing (MLMT), at year one

First Week Of August 18th Options Trading For Spark Therapeutics (ONCE)

Investors in Spark Therapeutics Inc saw new options become available this week, for the August 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ONCE options chain for the new August 18th contracts and identified one put and one call contract of particular interest.

Spark Therapeutics Completes Rolling Biologics License Application Submission To FDA for Investigational Gene Therapy Voretigene Neparvovec

Voretigene neparvovec has the potential to be the first pharmacologic treatment for an inherited retinal disease (IRD) and the first gene therapy for a genetic disease in the U.S.

We May Be Back to Maximum Overbought by Thursday

Breadth has a small window to improve from the poor and lagging action we saw last week.

Spark Therapeutics Reaches Analyst Target Price

In recent trading, shares of Spark Therapeutics Inc have crossed above the average analyst 12-month target price of $64.73, changing hands for $64.82/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Spark Therapeutics Announces $15 Million Milestone Payment From Pfizer For Progress In Hemophilia B Gene Therapy Program

Spark Therapeutics Announces $15 Million Milestone Payment From Pfizer For Progress In Hemophilia B Gene Therapy Program

Second milestone achieved under 2014 global license agreement with Pfizer

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting

I spent the weekend with thousands of blood disease researchers. This is what happened.

TheStreet Quant Rating: D (Sell)